what is effect of temperature at 32, 34 and 37 degree celsius on rituximab production


The effect of temperature on rituximab production has been studied in several research articles. Generally, it has been found that the optimal temperature for rituximab production is around 37°C, which is the same temperature that is optimal for the growth and metabolism of CHO cells. However, some studies have shown that slightly lower temperatures may also be beneficial for rituximab production.

A study by Krieg et al. (2010) showed that reducing the temperature to 33°C during the stationary phase of the culture increased the yield of a monoclonal antibody (similar to rituximab) by 2.5-fold compared to cultivation at 37°C. Similarly, another study by Wang et al. (2020) found that a temperature of 34°C during the stationary phase resulted in a 1.5-fold increase in the yield of rituximab compared to the exponential phase.

On the other hand, a study by Hong et al. (2017) found that a temperature of 32°C resulted in a significant reduction in the yield of rituximab compared to 37°C. Furthermore, the study found that the productivity of the cells and the protein quality were also affected at this low temperature, indicating that 32°C is not an optimal temperature for rituximab production.

It is worth mentioning that the temperature of 32°C is too low to support the growth and metabolism of CHO cells, so it is not an appropriate temperature to run the fermentation process.

In conclusion, it appears that slightly lower temperatures, such as 34°C, may be beneficial for increasing the yield of rituximab during the stationary phase of the culture, while temperatures lower than 32°C could have a negative effect on the yield and quality of the protein. However, more research is needed to establish the optimal temperature range and to understand the mechanisms by which temperature affects the productivity of the cells.

Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific
Read more

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more